JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
Add like
Add dislike
Add to saved papers

Characterizations of the extracellular matrix and proteinase inhibitor content of human myoepithelial tumors.

Myoepithelial tumors are intriguing low-grade neoplasms that exhibit the property of accumulating an abundant extracellular matrix. Because accumulation of an extracellular matrix represents an important exception to the rule of matrix degradation otherwise exhibited by the vast majority of human epithelial neoplasms, this study investigated the composition of this matrix to gain insight into the biological behavior of this class of neoplasms. Several different human myoepithelial tumors and their derived cell lines and xenografts were thus examined by ultrastructural, immunohistochemical, molecular, and biochemical methods. Results indicated that although the extracellular matrix of these tumors contains some basement membrane components such as laminin, nidogen, and heparan sulfate proteoglycan (8%), it is also largely cartilagenous in nature, containing large amounts of chondroitin sulfate proteoglycan (78%). In addition to extracellular matrix structural proteins, myoepithelial cells secreted relatively large amounts of proteinase inhibitors including maspin, protease nexin II, alpha1-antitrypsin, a 31-kd serine proteinase inhibitor, and TIMP-1. Immunolocalization and extraction studies further demonstrated that protease nexin II and alpha1-antitrypsin especially accumulated within the myoepithelial extracellular matrix. In addition, protease nexin II likely underwent extracellular in vivo processing to a 95-kd product retaining full proteinase inhibitor activity. These specific biochemical observations unite the classes of myoepithelial tumors, confer an anti-invasive property to their extracellular matrix, and likely contribute to their low-grade biological behavior.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app